Combination of Kiratathikta and Bhringaraja in Non alcoholic fatty liver disease.

A randomized controlled clinical trial to assess the efficacy of the combination of Kiratathikta [Andrographis paniculata (Burm. f.) Wall ex. Nees] and Bhringaraja [Eclipta prostrata (L.) L.] in Non alcoholic fatty liver disease against Dronapushpi [Leucas aspera (Willd.) Link.. Link.]

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/07/034920

Enrollment

Registered

2021-07-16

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified

Interventions

Intervention1: Kiratatiktha Bhringaraja Tablet: Form of the drug Trial drug - KB yoga in kashaya tablet form Dose of the drug Trial drug â?? Two tablets, together contain 950 mg of dried KB kashaya in

Eligibility

Inclusion criteria

Inclusion criteria: Should satisfy all of the following criteria 1. Participants diagnosed with fatty liver 2. With mildly to moderately elevated ALT and AST ( 3. ALT more than AST. 4. USG report confirming fatty liver disease taken within 6 months prior to the recruitment. 5. Age group 30 years â?? 60 years irrespective of gender 6. Those who are willing to participate in the trial

Exclusion criteria

Exclusion criteria: 1. Estimated average alcohol consumption > 20 g / day for men and > 10 g / day for women in the six months prior to enrolment 2. Participants having uncontrolled DM & HTN 11 3. Viral hepatitis, Wilsonâ??s disease 4. Drug induced fatty liver disease 5. Patients with liver cirrhosis 6. Patients taking Ayurvedic treatment for other diseases 7. Established cases of IHD / Stroke 8. Patients undergoing and completed Cancer treatment 9. Patients with Insulin therapy 10. Pregnancy or lactation 11. Patients in bed ridden condition

Design outcomes

Primary

Measure	Time frame
ALT and AST - before and after the treatment Timepoint: ALT and AST - before and after the treatment	—

Secondary

Measure	Time frame
Subjective parameters â?? Fatigue, Nausea, Weight loss, Anorexia, Dull ache in the right hypochondriac region â?? each of them will be converted into grades and before and after reading will be taken for comparison.Timepoint: Subjective parameters â?? Fatigue, Nausea, Weight loss, Anorexia, Dull ache in the right hypochondriac region â?? each of them will be converted into grades and before and after reading will be taken for comparison.	—

Measure

Time frame

Subjective parameters â?? Fatigue, Nausea, Weight loss, Anorexia, Dull ache in the right hypochondriac region â?? each of them will be converted into grades and before and after reading will be taken for comparison.Timepoint: Subjective parameters â?? Fatigue, Nausea, Weight loss, Anorexia, Dull ache in the right hypochondriac region â?? each of them will be converted into grades and before and after reading will be taken for comparison.

—

Countries

India

Contacts

Public ContactDr Vivek P

VPSV Ayurveda College

manojkumarndr@gmail.com9447423771

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026